title: The paradox of heparin-induced thrombocytopenia: future anticoagulation.
abstract: Heparin and low molecular weight heparin agents are frequently administered to postoperative orthopedic patients. In patients with a history of heparin-induced thrombocytopenia, alternative anticoagulant agents to heparin for prophylaxis and treatment must be considered. Unfortunately, the data is limited in this patient population. Upon transitioning from heparin-induced thrombocytopenia treatment with direct thrombin inhibitors, argatroban, or lepirudin, careful consideration must be taken to avoid further thrombotic complications.
authors.affiliation: University of Kentucky Chandler Medical Center, Lexington, Ky, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Taylor
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Smith
mesh_terms: D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D019637:Orthopedic Procedures; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000145:classification; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D007074:Immunoglobulin G; D006493:Heparin